Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some ...

Richard Ascroft, the company's chief executive officer for the North America business, stated that the Mumbai-based drug ...

Discover key Royalty Pharma Q3 2025 earnings insights—double-digit growth, new acquisitions, and raised guidance for investors.

Sun Pharma is considering expanding its manufacturing in the U.S. due to new tariffs on medicines. CEO Richard Ascroft ...

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

Ho next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, ...

Perrigo said on Wednesday it has initiated a strategic review of its infant formula business as the consumer health company shifts its focus to higher-margin branded products.

Data from Storyful found that users’ fears around AI in the therapy space are widespread. The report noted that one user on Reddit called AI driven therapy a “control system,” while others warned of ...